Business Context and Reporting Period
MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. This Form 10-Q covers the quarterly period ended March 31, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of May 12, 2025, there were 3,985,657 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,766,697) | $(3,813,295) |
| Net Loss Per Share (Basic & Diluted) | $(0.70) | $(1.10) |
| Cash and Cash Equivalents (End of Period) | $3,234,899 | $5,817,080 |
| Net Cash Used in Operating Activities | $(1,340,876) | $(2,542,207) |
| Total Assets | $4,267,313 | $5,720,813 |
| Total Current Liabilities | $12,120,067 | $6,959,676 |
| Accumulated Deficit | $(146,948,432) | $(137,210,228) |
Debt and Liquidity: The company holds a related party convertible promissory note with Agenus Inc. with a principal balance of $5.0 million and accrued interest of approximately $104,444 as of March 31, 2025. The note is due on or after January 1, 2026. The company reported a stockholders' deficit of $21.8 million.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased to $2.7 million in Q1 2025 from $3.8 million in Q1 2024.
- R&D Expenses: Decreased 51% to $1.3 million (from $2.5 million), driven by reduced clinical trial timing costs and lower personnel costs due to decreased headcount.
- G&A Expenses: Remained relatively flat at $1.3 million.
- Non-Cash Items: Q1 2025 included a $167,922 expense related to the change in fair value of the related party note, which was not present in Q1 2024.
- Cash Position: Cash and cash equivalents declined by approximately $1.3 million during the quarter, compared to an increase of $2.4 million in the prior year quarter (which included $5.0 million in proceeds from the related party note).
- Capital Structure: A 1-for-10 reverse stock split was effected on January 28, 2025. All share and per-share data in the filing have been retroactively adjusted.
Guidance, Outlook, Risks, and Contingencies
Going Concern: Management has disclosed that substantial doubt exists regarding the company's ability to continue as a going concern for one year following the filing date. The company expects to continue incurring operating losses and requires additional funding to satisfy liquidity requirements. Potential funding sources include strategic partnerships, non-dilutive financing (grants), and equity or debt financing.
Operational Outlook:
- agenT-797: Advancing in Phase 2 trials for gastric cancer and viral ARDS. A randomized Phase 2 trial in gastric cancer is actively enrolling.
- Pipeline: Next-generation engineered programs MiNK-215 and MiNK-413 are in preclinical stages, with IND submission expected in 2025.
- Collaborations: Active collaboration with ImmunoScape for T-cell receptor discovery.
Risks and Contingencies:
- Nasdaq Compliance: On May 13, 2025, the company received notice from Nasdaq that its Minimum Value of Listed Securities (MVLS) fell below the $35.0 million requirement. The company has 180 days (until November 10, 2025) to regain compliance or face delisting.
- Legal: The company has a contingent liability of approximately $2.3 million related to a default judgment from the Belgium Walloon Region Government regarding a research and development agreement advance.
- Related Party Dependence: The company relies on Agenus for administrative support and holds a significant related party note. Agenus has agreed not to require repayment of the "Due to related parties" balance of $13.9 million for the foreseeable future.
Investor Verification Checklist
- Liquidity Runway: Verify the status of anticipated funding sources required to sustain operations beyond the current cash balance of $3.2 million.
- Nasdaq Delisting Risk: Monitor the company's MVLS and any announced plans (e.g., capital raises, reverse splits) to regain compliance by November 10, 2025.
- Related Party Note Terms: Review the conversion terms of the $5.0 million Agenus note, particularly the 80% discount conversion rate in a qualified financing event.
- Walloon Region Liability: Assess the status of the $2.3 million contingent liability and any ongoing legal proceedings.
- Reverse Stock Split Impact: Confirm the post-split share count and trading status on Nasdaq Capital Market.